Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinomaReport as inadecuate




Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma - Download this document for free, or read online. Document in PDF available to download.

BMC Cancer

, 6:3

First Online: 05 January 2006Received: 05 October 2005Accepted: 05 January 2006DOI: 10.1186-1471-2407-6-3

Cite this article as: Park, S.H., Lee, Y., Han, S.H. et al. BMC Cancer 2006 6: 3. doi:10.1186-1471-2407-6-3

Abstract

BackgroundAlthough numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma HCC has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed this study with new effective drug combination.

MethodsTwenty-nine patients with histologically-confirmed, metastatic HCC received a combination chemotherapy with doxorubicin 60 mg-m and cisplatin 60 mg-m on day 1, plus capecitabine 2000 mg-m-day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest.

ResultsThe median age was 49 years range, 32–64 and 19 patients were hepatitis B virus seropositive. Child-Pugh class was A in all patients and 4 had Zubrod performance status of 2. The objective response rate was 24% 95% CI 9–40 with 6 stable diseases. The chemotherapy was generally well tolerated despite one treatment-related death.

ConclusionCombination chemotherapy with doxorubicin, cisplatin and capecitabine produced modest antitumor activity with tolerable adverse effects in patients with metastatic HCC.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-6-3 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Se Hoon Park - Yuna Lee - Sang Hoon Han - So Young Kwon - Oh Sang Kwon - Sun Suk Kim - Ju Hyun Kim - Yeon Ho Park -

Source: https://link.springer.com/







Related documents